The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...

The EU Commission said Teva's actions may have prevented significant savings by countries across Europe, with other versions of the drug possibly 80% cheaper than Copaxone. Teva will have to pay a ...

The European Commission has fined Israeli drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) EUR 462.6M, or around $500M, for trying to ward off competition for its blockbuster multiple sclerosis ...

To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in Europe containing glatiramer acetate, the commission said in a statement.

To do that, Teva conducted a "disparagement campaign" against Synthon, the only other company with an authorised drug in Europe containing glatiramer acetate, the Commission said in a statement.